Cell News and Research

RSS

Poniard Pharmaceuticals may sell up to $60 million of its registered common stock to finance its picoplatin clinical development and commercialization programs

...

20 Aug 2009

Advaxis awarded $210,000 for development of a dual antigen vaccine

Advaxis, Incorporated (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, has been awarded a $210,000 grant from the US National Institute of Health (NIH) to develop a single bioengineered Lm vaccine to deliver two different antigen-adjuvant proteins.

20 Aug 2009

Shape-changing in proteins opens new avenue for drug discovery

Computational biologists at the University of Pittsburgh School of Medicine have shown that proteins have an intrinsic ability to change shape, and this is required for their biological activity. This shape-changing also allows the small molecules that are attracted to a given protein to select the structure that permits the best binding. That premise could help in drug discovery and in designing compounds that will have the most impact on protein function to better treat a host of diseases.

20 Aug 2009

Fluxion Biosciences receives a $1.8 million NIH grant for developing microfluidic platform

Fluxion Biosciences, a leading developer of microfluidic systems for functional cell analysis, today announced that it has received a $1.8 million NIH grant for the development of a high-throughput screening platform for anti-microbial drug discovery.

From Fluxion Biosciences 20 Aug 2009

USPTO grants MultiCell Technologies patent for its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines

MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) announced today it has been granted U.S. patent 7,566,567 by the United States of America Patent and Trademark Office covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines.

20 Aug 2009

Mesenchymal stem cells repair human brain

There is no known cure for neurodegenerative diseases such as Huntington's, Alzheimer's and Parkinson's. But new hope, in the form of stem cells created from the patient's own bone marrow, can be found ― and literally seen ― in laboratories at Tel Aviv University.

20 Aug 2009

Consumer-friendly "finger stick" blood test to detect cardiovascular disease is broadly available now

A new blood test, measuring the level of omega-3 fatty acids in red blood cells, is now broadly available for the first time to the public everywhere as a consumer-friendly, at-home "finger stick" test. While scientists have long known of the benefits of fish and fish oil for overall heart health, over the past decade research has proven that the omega-3 fatty acids found in fish dramatically reduce one's risk for cardiovascular disease. Further, recent research indicates that omega-3 levels may be among the best predictors of future coronary heart disease - providing much stronger correlations to the risk of sudden cardiac death than traditional indicators, including HDL and LDL cholesterol.

20 Aug 2009

Novel microRNA plays a major role in invasive breast cancer development

Research led by Suresh Alahari, PhD, Associate Professor of Biochemistry and Molecular Biology at LSU Health Sciences Center New Orleans, has shown for the first time that a tiny piece of RNA appears to play a major role in the development of invasive breast cancer and identified a gene that appears to inhibit invasive breast cancer.

20 Aug 2009

Peplin completes four-week enrolment phase for REGION-Ib trial

Peplin, Inc. (ASX:PLI) today announced completion of enrolment in its second Phase 3 clinical trial for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, on non-head treatment areas, which include the trunk and extremities. This completes enrolment in the final of four pivotal trials planned for the submission of the New Drug Application (NDA) for AK.

20 Aug 2009

Scientists find another mechanism that destroys tumor cells

Cells don't like to be alone. In the early stages of tumor formation, a cell might be pushed out of its normal home environment due to excessive growth. But a cell normally responds to this homeless state by dismantling its nucleus, packing up its DNA, and offering itself to be eaten by immune system cells. Simply put, the homeless cell kills itself. This process, known as apoptosis, typically stops potential cancer cells before they have a chance to proliferate.

20 Aug 2009

Managing Myeloma educational website launches forum to encourage oncology nurses to discuss myeloma challenges

Managing Myeloma (www.ManagingMyeloma.com), an accredited educational website for multidisciplinary professionals, has launched a forum designed specifically for oncology nurses. The goal of the nursing forum is to share insight about day-to-day practice challenges in caring for patients with multiple myeloma, provide updates on clinical advances, and connect with peers.

20 Aug 2009

New strategy found to increase the efficacy of protein-based drugs

A new method for attaching a large protective polymer molecule to a protein appears to improve protein drugs significantly.

20 Aug 2009

UT Southwestern Medical Center: Human gut bacteria ward off Toxoplasma gondii

Immunology researchers at UT Southwestern Medical Center have found that bacteria present in the human gut help initiate the body's defense mechanisms against Toxoplasma gondii, the parasite responsible for toxoplasmosis.

20 Aug 2009

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Inovio Biomedical Corporation (NYSE AMEX: INO) (“Inovio”) today reported financial results for the three and six months ended June 30, 2009. Total revenue of $2.5 million and $2.9 million for the three and six months ended June 30, 2009, compared to $663,000 and $1.3 million for the three and six months ended June 30, 2008, respectively.

20 Aug 2009

Poll reveals that thin majority of Americans continue to support health care reforms

A slim majority of Americans continues to favor moving forward on health care reform now despite an intensifying ad war and a political climate of contentious town hall meetings that coincide with rising concerns about the reform effort, according to the August Kaiser Health Tracking Poll.

20 Aug 2009

Study finds long-term exposure to progesterone may lead to growth of tumors

Scientists at Michigan State University have found exposure to the hormone progesterone activates genes that trigger inflammation in the mammary gland.

20 Aug 2009

Institutional investor buys $30 million of convertible stock and warrants in Cell Therapeutics

Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.

20 Aug 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.

20 Aug 2009

Scientists develop new technique to target brain cancer cells

Scientists from the U.S. Department of Energy's (DOE) Argonne National Laboratory and the University of Chicago's Brain Tumor Center have developed a way to target brain cancer cells using inorganic titanium dioxide nanoparticles bonded to soft biological material.

20 Aug 2009

Steroid hormones found to affect gene activity

Intermittent signaling by steroid hormones can affect the way genes are expressed in rodents, according to research by scientists at the University of Bristol and the National Cancer Institute (NCI), USA. This work has major implications for understanding how steroids work and opens novel avenues for new therapies.

19 Aug 2009

Cell News and Research

Poniard Pharmaceuticals may sell up to $60 million of its registered common stock to finance its picoplatin clinical development and commercialization programs

Advaxis awarded $210,000 for development of a dual antigen vaccine

Shape-changing in proteins opens new avenue for drug discovery

Fluxion Biosciences receives a $1.8 million NIH grant for developing microfluidic platform

USPTO grants MultiCell Technologies patent for its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines

Mesenchymal stem cells repair human brain

Consumer-friendly "finger stick" blood test to detect cardiovascular disease is broadly available now

Novel microRNA plays a major role in invasive breast cancer development

Peplin completes four-week enrolment phase for REGION-Ib trial

Scientists find another mechanism that destroys tumor cells

Managing Myeloma educational website launches forum to encourage oncology nurses to discuss myeloma challenges

New strategy found to increase the efficacy of protein-based drugs

UT Southwestern Medical Center: Human gut bacteria ward off Toxoplasma gondii

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Poll reveals that thin majority of Americans continue to support health care reforms

Study finds long-term exposure to progesterone may lead to growth of tumors

Institutional investor buys $30 million of convertible stock and warrants in Cell Therapeutics

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Scientists develop new technique to target brain cancer cells

Steroid hormones found to affect gene activity

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News